高风险腺瘤内镜切除后异时性结直肠癌或进展期腺瘤的危险因素
该系统综述与荟萃分析纳入55项队列研究和临床试验、共936,540例患者,评估基线高风险腺瘤特征与异时性结直肠癌或进展期腺瘤风险的关联。结果显示,腺瘤≥20 mm或高级别异质增生时异时性结直肠癌风险最高,而多发腺瘤在近期内似乎与结直肠癌风险显著升高无关。
要点
- 基线腺瘤≥20 mm或伴高级别异质增生者异时性结直肠癌风险最高。
- 腺瘤≥20 mm相比10至19 mm的RR为2.08(95%CI 1.20-3.61)。
- 多发腺瘤(≥3个或≥5个)在近期内似乎与结直肠癌风险显著升高无关。
核心结论
- 基线腺瘤≥20 mm或伴高级别异质增生的患者异时性结直肠癌风险最高。
- 多发腺瘤在近期内似乎与结直肠癌风险显著升高无关。
研究设计与样本
- 系统检索Pubmed、EMBASE和Cochrane数据库中的队列研究和临床试验,纳入55项研究、共936,540例患者,平均随访5.4±2.9年。
- 按基线病变大小、组织学和多发性分层,计算异时性结直肠癌或进展期腺瘤发生率的合并相对危险度(RR),采用随机效应模型,异质性用I²统计量评估。
主要发现
- 每1000人年的结直肠癌发生率:腺瘤≥20 mm为2.6(2.1-3.0),高级别异质增生为2.7(2.2-3.2),绒毛状成分为2.0(1.8-2.3),≥5个腺瘤为0.8(0.1-1.4),≥3个腺瘤为1.0(0.7-1.2)。
- 异时性结直肠癌风险:腺瘤≥20 mm相比10至19 mm的RR为2.08(95%CI 1.20-3.61),高级别异质增生相比低级别异质增生的RR为2.89(95%CI 1.88-4.44),绒毛状相比管状的RR为1.75(95%CI 1.33-2.31)。
- ≥3个腺瘤相比1至2个腺瘤的结直肠癌风险RR为1.24(95%CI 0.84-1.83),≥5个腺瘤相比3至4个腺瘤的RR为0.79(95%CI 0.30-2.11),均无显著差异。
- 相比正常结肠镜检查,结直肠癌风险RR:≥10 mm为2.61(95%CI 2.06-3.32),高级别异质增生为6.62(95%CI 4.60-9.52),绒毛状成分为3.58(95%CI 2.24-5.73),≥3个腺瘤为2.03(95%CI 1.40-2.94)。
- 异时性进展期腺瘤呈现相似趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Among the characteristics of high-risk adenomas (HRAs), some may predict a higher risk of metachronous advanced lesions. Our aim was to assess which HRA characteristics are associated with high risk of metachronous colorectal cancer (CRC) or advanced adenomas (AAs). METHODS: We systematically searched Pubmed, EMBASE, and Cochrane for cohort studies and clinical trials of CRC or AA incidence at surveillance stratified by baseline lesion size, histology, and multiplicity. We calculated pooled relative risks (RRs) using a random-effects model. Heterogeneity was assessed with the I2 statistic. RESULTS: Fifty-five studies were included, with 936,540 patients with mean follow-up 5.4 ± 2.9 years. CRC incidence per 1000 person-years was 2.6 (2.1-3.0) for adenomas ≥20 mm, 2.7 (2.2-3.2) for high-grade dysplasia (HGD), 2.0 (1.8-2.3) for villous component, 0.8 (0.1-1.4) for ≥5 adenomas, 1.0 (0.7-1.2) for ≥3 adenomas. Metachronous CRC risk was higher in adenomas ≥20 mm vs 10 to 19 mm (RR, 2.08; 95% confidence interval [CI], 1.20-3.61), HGD vs low-grade dysplasia (RR, 2.89; 95% CI, 1.88-4.44), villous vs tubular (RR, 1.75; 95% CI, 1.33-2.31). No significant differences in CRC risk were found in ≥3 adenomas vs 1 to 2 (RR, 1.24; 95% CI, 0.84-1.83), nor in ≥5 adenomas vs 3 to 4 (RR, 0.79; 95% CI, 0.30-2.11). Compared with normal colonoscopy, RR for CRC risk was 2.61 (95% CI, 2.06-3.32) for ≥10mm, 6.62 (95% CI, 4.60-9.52) for HGD, 3.58 (95% CI, 2.24-5.73) for villous component, and 2.03 (95% CI, 1.40-2.94) for ≥3 adenomas. Similar trends were seen for metachronous AAs. CONCLUSION: Metachronous CRC risk is highest in patients with baseline adenomas with ≥20 mm or HGD. Multiplicity does not seem to be associated with substantially higher CRC risk in the near term.
引用
- Baile-Maxía S, Mangas-Sanjuán C, Ladabaum U, et al. Risk Factors for Metachronous Colorectal Cancer or Advanced Adenomas After Endoscopic Resection of High-risk Adenomas. Clin Gastroenterol Hepatol. 2022. PMID: 36549471. doi:10.1016/j.cgh.2022.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。